SILO Stock Analysis
SI
Uncovered
Silo Pharma Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in merging traditional therapeutics with psychedelic research. The company is headquartered in Englewood Cliffs, New Jersey. The company went IPO on 2012-01-05. The company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Parkinson’s and other neurological disorders. The company focuses on identifying assets to license and fund the research for the well-being of patients and the healthcare industry. The company has entered into a license agreement with the University of Baltimore, Maryland, and has entered into a joint venture with Zylo Therapeutics, Inc., with respect to certain intellectual property and technology that may be used for delivery of potential novel treatments. The company has entered into a sponsored research agreement with Columbia University, pursuant to which it has been granted an option to license certain patents and inventions relating to the treatment of Alzheimer’s disease and stress-induced affective disorders using Ketamine in combination with certain other compounds.